News & Press
Tyra Biosciences raises $106M in Series B financing to advance novel pipeline of therapies targeting acquired resistance in oncology
– Financing led by Nextech Invest with participation from Cormorant Asset Management, BVF Partners, L.P., Janus Henderson Investors, and Logos, along with existing investors Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan – Hiroomi Tada, MD,...
Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology
– Round co-led by Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan, representing a group of seasoned early-stage and crossover investors – Experienced team well positioned to tackle acquired resistance, a devastating reality for patients...
